Role of matrix metalloproteinase MMP-2, MMP-9 and tissue inhibitor of metalloproteinase (TIMP-1) in the clinical progression of pediatric acute lymphoblastic leukemia

References

• Hunger SP, Mullighan CG. Redefining ALL classification: toward detecting high-risk ALL and implementing precision medicine. Blood. 2015;125:3977–3987.
   PubMed Web of Science ®Google Scholar
• Shafat MS, Gnaneswaran B, Bowles KM, et al. The bone marrow microenvironment-home of the leukemic blasts. Blood Rev. 2017;31:277–286.
   PubMed Web of Science ®Google Scholar
• Pui CH, Behm FG, Singh B, et al. Heterogeneity of presenting features and their relation to treatment outcome in120children with T cell acute lymphoblastic leukemia. Blood. 1990;75(1):174–179.
   PubMed Web of Science ®Google Scholar
• Somers K, Evans K, Cheung L, et al. Effective targeting of NAMPT in patient-derived xenograft models of high-risk pediatric acute lymphoblastic leukemia. Leukemia. 2020 Jun;34(6):1524–1539.
   PubMed Web of Science ®Google Scholar
• Tran TH, Harris MH, Nguyen JV, et al. Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia. Blood Adv. 2018;2:529–533.
   PubMed Web of Science ®Google Scholar
• Huang FL, Liao EC, Li CL, et al. Pathogenesis of pediatric B-cell acute lymphoblastic leukemia: Molecular pathways and disease treatments. Oncol Lett. 2020 Jul;20(1):448–454. doi:https://doi.org/10.3892/ol.2020.11583.
   PubMed Web of Science ®Google Scholar
• Gaudichon J, Jakobczyk H, Debaize L, et al. Mechanisms of extramedullary relapse in acute lymphoblastic leukemia: reconciling biological concepts and clinical issues. Blood Rev. 2019 Jul;36:40–56.
   PubMed Web of Science ®Google Scholar
• Paganin M, Fabbri G, Conter V, et al. Postinduction minimal residual disease monitoring by polymerase chain reaction in children with acute lymphoblastic leukemia. J Clin Oncol. 2014;32:3553–3558.
   PubMed Web of Science ®Google Scholar
• Lane SW, Scadden DT, Gilliland DG. The leukemic stem cell niche: current concepts and therapeutic opportunities. Blood. 2009;114:1150–1157.
   PubMed Web of Science ®Google Scholar
• Yu Y, Ramena G, Elble RC. The role of cancer stem cells in relapse of solid tumors. Front Biosci. 2012;4:1528–1541.
   Google Scholar
• Chu S, McDonald T, Lin A, et al. Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. Blood. 2011;118:5565–5572.
   PubMed Web of Science ®Google Scholar
• Kihira K, Chelakkot VS, Kainuma H, et al. Close interaction with bone marrow mesenchymal stromal cells induces the development of cancer stem cell-like immunophenotype in B cell precursor acute lymphoblastic leukemia cells. Int J Hematol. 2020 Dec;112(6):795–806. doi:https://doi.org/10.1007/s12185-020-02981-z. Epub 2020 Aug 30. PMID: 32862292.
   PubMed Web of Science ®Google Scholar
• Brennan L, Narendran A. Cancer stem cells in the development of novel therapeutics for refractory pediatric leukemia. Stem Cells Dev. 2019 Oct 1;28(19):1277–1287. doi:https://doi.org/10.1089/scd.2019.0035.
   PubMed Web of Science ®Google Scholar
• Christopherson KW, Cooper S, Hangoc G, et al. CD26 is essential for normal G-CSF-induced progenitor cell mobilization as determined by CD26−/− mice. Exp Hematol. 2003;31:1126–1134.
   PubMed Web of Science ®Google Scholar
• Klein G, Schmal O, Aicher WK. Matrix metalloproteinases in stem cell mobilization. Matrix Biol. 2015;44–46:175–183.
   PubMed Web of Science ®Google Scholar
• Mehner C, Hockla A, Miller E, et al. Tumor cell-produced matrix metalloproteinase 9 (MMP-9) drives malignant progression and metastasis of basal-like triple negative breast cancer. Oncotarget. 2014;5:2736–2749.
   PubMedGoogle Scholar
• Reggiani F, Labanca V, Mancuso P, et al. Adipose progenitor cell secretion of GM-CSF and MMP-9 promotes a stromal and immunological microenvironment that supports breast cancer progression. Cancer Res. 2017;77:5169–5182.
   PubMed Web of Science ®Google Scholar
• Rydlova M, Holubec Jr. L, Ludvikova Jr. M, et al. Biological activity and clinical implications of the matrix metalloproteinases. Anticancer Res. 2008;28:1389–1397.
   PubMed Web of Science ®Google Scholar
• Hsiao YH, Su SC, Lin CW, et al. Pathological and therapeutic aspects of matrix metalloproteinases: implications in childhood leukemia. Cancer Metastasis Rev. 2019 Dec;38(4):829–837.
   PubMed Web of Science ®Google Scholar
• Kapoor C, Vaidya S, Wadhwan V, et al. Seesaw of matrix metalloproteinases (MMPs). J Cancer Res Ther. 2016;12(1):28.
   PubMed Web of Science ®Google Scholar
• Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002;2:161–174.
   PubMed Web of Science ®Google Scholar
• Dos Reis ST, Viana NI, Iscaife A, et al. Loss of TIMP-1 immune expression and tumor recurrence in localized prostate cancer. Int Braz J Urol. 2015;41(6):1088–1095.
   PubMed Web of Science ®Google Scholar
• Dechaphunkul A, Phukaoloun M, Kanjanapradit K, et al. Prognostic significance of tissue inhibitor of metalloproteinase-1 in breast cancer. Int J Breast Cancer. 2012;2012:290854.
   PubMedGoogle Scholar
• Rettori MM, De carvalho AC, Bomfim longo AL, et al. Prognostic significance of TIMP3 hypermethylation in post-treatment salivary rinse from head and neck squamous cell carcinoma patients. Carcinogenesis. 2013;34(1):20–27.
   PubMed Web of Science ®Google Scholar
• Jackson HW, Defamie V, Waterhouse P, et al. TIMPs: versatile extracellular regulators in cancer. Nat Rev Cancer. 2017 Jan;17(1):38.
   PubMed Web of Science ®Google Scholar
• Winer A, Adams S, Mignatti P. Matrix metalloproteinase inhibitors in cancer therapy: turning past failures into future successes. Mol Cancer Ther. 2018 Jun 1;17(6):1147–1155.
   PubMed Web of Science ®Google Scholar
• Daniel AA, Attilio O, Robert H, et al. Revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405.
   PubMed Web of Science ®Google Scholar
• Campana D. Minimal residual disease in acute lymphoblastic leukemia. Semin Hematol. 2009;46(1):100–106.
   PubMed Web of Science ®Google Scholar
• Pui CH, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med. 2009 Jun 25;360(26):2730–2741.
   PubMed Web of Science ®Google Scholar
• Kuittinen O, Savolainen ER, Koistinen P, et al. MMP-2 and MMP-9 expression in adult and childhood acute lymphatic leukemia (ALL). Leuk Res. 2001 Feb;25(2):125–131.
   PubMed Web of Science ®Google Scholar
• Lin LI, Lin DT, Chang CJ, et al. Marrow matrix metalloproteinases (MMPs) and tissue inhibitors of MMP in acute leukaemia: potential role of MMP-9 as a surrogate marker to monitor leukaemic status in patients with acute myelogenous leukaemia. Br J Haematol. 2002 Jun;117(4):835–841.
   PubMed Web of Science ®Google Scholar
• Verma D, Zanetti C, Godavarthy PS, et al. Bone marrow niche-derived extracellular matrix-degrading enzymes influence the progression of B-cell acute lymphoblastic leukemia. Leukemia. 2020 Jun;34(6):1540–1552.
   PubMed Web of Science ®Google Scholar
• Kaczorowska A, Miękus N, Stefanowicz J, et al. Selected matrix metalloproteinases (MMP-2, MMP-7) and their inhibitor (TIMP-2) in adult and pediatric cancer. Diagnostics (Basel). 2020 Jul 31;10(8):547.
   Google Scholar
• Scrideli CA, Cortez MA, Yunes JA, et al. mRNA expression of matrix metalloproteinases (MMPs) 2 and 9 and tissue inhibitor of matrix metalloproteinases (TIMPs) 1 and 2 in childhood acute lymphoblastic leukemia: potential role of TIMP-1 as an adverse prognostic factor. Leuk Res. 2010 Jan;34(1):32–37.
   PubMed Web of Science ®Google Scholar
• Schneider P, Costa O, Legrand E, et al. In vitro secretion of matrix metalloprotease 9 is a prognostic marker in childhood acute lymphoblastic leukemia. Leuk Res. 2010 Jan;34(1):24–31.
   PubMed Web of Science ®Google Scholar
• Madhusoodhan PP, Carroll WL, Bhatla T. Progress and prospects in pediatric leukemia. Curr Probl Pediatr Adolesc Health Care. 2016 Jul;46(7):229–241.
   PubMed Web of Science ®Google Scholar
• Kihira K, Chelakkot VS, Kainuma H, et al. Close interaction with bone marrow mesenchymal stromal cells induces the development of cancer stem cell-like immunophenotype in B cell precursor acute lymphoblastic leukemia cells. Int J Hematol. 2020 Dec;112(6):795–806.
   PubMed Web of Science ®Google Scholar
• Brennan L, Narendran A. Cancer stem cells in the development of novel therapeutics for refractory pediatric leukemia. Stem Cells Dev. 2019 Oct 1;28(19):1277–1287. Mudry.
   PubMed Web of Science ®Google Scholar
• Mudry RE, Fortney JE, York T, et al. Stromal cells regulate survival of B-lineage leukemic cells during chemotherapy. Blood. 2000;96:1926–1932.
   PubMed Web of Science ®Google Scholar